|Summary sheet: DMXE|
|Psychoactive class||Dissociative / Hallucinogen|
|Routes of Administration|
DMXE has been sold online since around October 2022, marketed as a legal replacement for MXE. 
Limited data exists about the pharmacological properties, metabolism, and toxicity of DMXE in humans, and it has a limited history of human use. It is highly advised to use harm reduction practices if using this substance.
History and culture
DMXE, like the majority of dissociatives, belongs to the class of arylcyclohexylamines. It is derived from MXE, having the methoxy residue replaced with a methyl residue . DMXE's molecular formula therefore lacks an oxygen, which results in more hydrophobic and less bulky structure - causing the slight differences in pharmacology.
DMXE acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
An in silico study showed that DMXE binds to the same site of NMDARs as MXE and posseses comparable potency 
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
If applicable, a brief summary of the substance's visual effects profile may be written here.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
- The general head space of DMXE, like MXE, is often described as particularly euphoric and clear-headed in comparison to that of DXM and ketamine.
There are currently 0 experience reports which describe the effects of this substance in our experience index.
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational DMXE use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown.
This is because DMXE is a research chemical with a very brief history of human usage.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
This dangerous interactions section is a stub.
As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
(List along order below)
- APA formatted reference
Please see the citation formatting guide if you need assistance properly formatting citations.
- Alert from NDEWS Web Monitoring team: Increases in Reddit discussions of DMXE, October 2020–March 2021 | https://ndews.org/?wysija-page=1&controller=email&action=view&email_id=125&wysijap=subscriptions
- Irie, T., Yanase, Y., Demizu, Y., Usami, M., & Kikura-Hanajiri, R. (2022). Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. In Journal of Pharmacological Sciences (Vol. 150, Issue 4, pp. 233–243). Elsevier BV.